MONORES ® is indicated in the treatment of bronchial asthma and chronic obstructive bronchopathy characterized by an asthmatic component.MONORES ® is a specialty based on Clenbuterol, an active ingredient listed among the selective agonists of Beta 2 adrenergic receptors. At the opening of the other sympathomimetic amines with selectivity towards the aforementioned receptors,
Clenbuterol also binds with high affinity the Beta 2 adrenergic receptors expressed by the tracheobronchial smooth muscle, determining a sensitive bronchodilation important in restoring the correct patency of the respiratory tract. The contextual fluidifying action on nasal mucus secretions makes the mucus significantly more fluid, thus facilitating its elimination through ciliary mucus clearance, and further improving the patient’s ventilatory capacity.
Following administration of MONORES ®, the absorbed portion of Clenbuterol is subsequently eliminated via the kidney. Beta2-agonist clenbuterol induced changes in the distribution of white blood cells in rats. Shirato K, Tanihata J, Motohashi N, Tachiyashiki K, Tomoda A, Imaizumi K. Experimental study that tests the immunological effects related to the use of Clenbuterol, demonstrating how this drug can cause a redistribution of white blood cells by increasing the number of neutrophils and monocytes at the expense of eosinophils and lymphocytes.
CLENBUTEROL IN THE TREATMENT OF OBSTRUCTIVE PATHOLOGIES OF THE AIRWAYS
Zhonghua Yi Xue Za Zhi (Taipei). 1991 Jan; 47 (1): 13-7. Spiropent (clenbuterol): another choice for patients with chronic reversible airways obstruction. Work that demonstrates how the use of Clenbuterol can represent a valid choice, both in terms of therapeutic efficacy and costs, for the long-term treatment of obstructive airway diseases, even reversible ones.